Trial Profile

Phase I Evaluation of Combination CLK/DYRK (Cirtuvivint) Inhibition with PARP Inhibition (Olaparib) in BRCA/HRD Platinum Resistant Ovarian Cancer

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 12 Jan 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

22 Dec 2025 According to Biosplice Therapeutics media release, this trial is sponsored by UCHealth University of Colorado Hospital and led by principal investigator Bradley R. Corr, MD, associate professor and director of clinical research in gynecologic oncology at the University of Colorado Anschutz.
22 Dec 2025 According to Biosplice Therapeutics media release, first patient has been dosed in this Investigator-Initiated Phase 1 trial.
22 Sep 2025 Status changed from not yet recruiting to recruiting.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com